Stage IV Non-Small Cell Lung Cancer AJCC v7 Clinical Trial
Official title:
A Phase I/II Open-Label Dose Escalation Trial of CPI-613 in Combination With Docetaxel Chemotherapy as a Second-Line Treatment of Non-Small-Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of 6,8-bis(benzylthio)octanoic acid (CPI-613) when given together with docetaxel and to see how well they work in treating patients with stage IIIB or IV non-small cell lung cancer. Drugs used in chemotherapy, such as CPI-613 and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
PRIMARY OBJECTIVES:
I. To determine the maximum tolerate dose (MTD) of CPI-613 when used in combination with
docetaxel therapy in advanced stage non-small cell lung cancer (NSCLC). (Phase1) II. To
evaluate the response rate in patients receiving CPI-613 in combination with docetaxel
therapy. (Phase 2)
SECONDARY OBJECTIVES:
I. To determine the safety of CPI-613 addition to docetaxel therapy. II. To determine the
progression-free survival with CPI-613 in combination with docetaxel therapy at 27 weeks.
III. To determine the median progression-free survival with CPI-613 in combination with
docetaxel therapy.
OUTLINE: This is a phase I, dose-escalation study of CPI-613 followed by a phase II study.
Patients receive CPI-613 intravenously (IV) over 2 hours on days 1 and 3, and docetaxel IV on
day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease
progression or unacceptable toxicity. Patients that achieve stable disease after 6 courses
then receive CPI-613 alone on days 1and 3. Courses repeat every 21 days for up to 2 years in
the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days and then
periodically for 2 years.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01642251 -
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00096265 -
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT03229278 -
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
|
Phase 1 | |
| Completed |
NCT01725165 -
Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT02408016 -
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
|
Phase 1/Phase 2 | |
| Completed |
NCT01866410 -
Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03066206 -
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT03299088 -
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
|
Phase 1 | |
| Completed |
NCT00693992 -
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
|
Phase 3 | |
| Terminated |
NCT02846792 -
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02503358 -
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT01727076 -
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02696993 -
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT03492801 -
Collection of Blood Samples in Patients With Non-small Cell Lung Cancer
|
||
| Completed |
NCT03520842 -
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT03455556 -
Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT00698815 -
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
|
Phase 2 |